

# A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women

Max Norman Tandrup Lambert, Lin Meng Hu, and Per Bendix Jeppesen

Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark

## ABSTRACT

**Background:** Age-related estrogen deficiency leads to accelerated bone resorption. There is evidence that, through selective estrogen receptor modulation, isoflavones may exert beneficial effects against estrogen-deficient bone loss. Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency.

**Objective:** To summarize evidence, we executed a systematic review and meta-analysis examining isoflavone therapies and bone mineral density (BMD) loss in peri- and postmenopausal women.

**Design:** We systematically searched EMBASE and PubMed for randomized controlled trials (RCTs) evaluating isoflavone therapies for treating BMD loss at the lumbar spine and femoral neck in estrogen-deficient women. Separate meta-analyses were carried out with the use of random-effects models for the lumbar spine and femoral neck for all studies providing isoflavones as aglycones.

**Results:** Twenty-six RCTs ( $n = 2652$ ) were included in the meta-analysis. At the lumbar spine, isoflavone treatment was associated with a significantly ( $P < 0.00001$ ) higher weighted mean difference (WMD) of BMD change of 0.01 (95% CI: 0.01, 0.02) than the control. For the femoral neck (18 RCTs,  $n = 1604$ ), isoflavone treatment showed a significantly ( $P < 0.01$ ) higher WMD of BMD change of 0.01 (95% CI: 0.00, 0.02) compared with the control. When isolating studies that provide isoflavone aglycones in their treatment arm, the average effect was further significantly increased at the spine (5 RCTs,  $n = 682$ ) to 0.04 ( $P < 0.00001$ ; 95% CI: 0.02, 0.05) and femoral neck (4 RCTs,  $n = 524$ ) to 0.03 ( $P < 0.05$ ; 95% CI: 0.00, 0.06) compared with the control. This protective effect against bone loss disappeared when only studies with formulations comprising predominantly isoflavone glycosides were included.

**Conclusions:** Isoflavone treatments exert a moderately beneficial effect against estrogen-deficient bone loss in women. The effect appears dependent on whether isoflavone treatments are in aglycone form; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones. *Am J Clin Nutr* 2017;106:801–11.

**Keywords:** isoflavone, bone, estrogen deficiency, osteopenia, osteoporosis

## INTRODUCTION

A natural decline in endogenous estrogen synthesis during menopause reduces bone mineral density (BMD) and incurs

negative changes to bone microarchitecture, increasing the risk of osteoporosis and, as a consequence, fracture risk in women (1, 2). Because of estrogen dysregulation and deficiency, menopausal women lose a mean of 2–5% BMD/y, and postmenopausal women lose a mean of 1–3% BMD/y (3, 4).

Randomized controlled trials (RCTs) support that estrogen therapies (ETs) are effective in the prevention and treatment of accelerated bone resorption in estrogen-deficient women (5, 6). These effects are largely caused by estrogen-mediated agonistic action through estrogen receptor (ER)  $\alpha$  and ER $\beta$  (7). Increased cancer risk has been associated with ETs, likely due to excessive stimulation of ER $\alpha$  by ETs in sensitive tissues such as the breasts, ovaries, and endometrium, all of which retain high ER $\alpha$  expression (8). As such, there is medical value in identifying surrogate bioactive substances with minimized and/or eliminated side effects of hormone therapies (9, 10). Isoflavones are naturally present in certain dietary legumes and can selectively modulate ERs; in contrast, ET isoflavones have selective affinity for ER $\beta$  (11, 12). ER $\beta$  is expressed in tissues requiring certain stimulation by estrogen to function optimally (e.g., bone tissue, bone marrow, adipose, brain, kidney, endothelial cells, and liver) (13). Researchers have sought to harness this selective affinity for targeting tissues to more safely and effectively treat estrogen-deficient bone resorption and BMD loss in estrogen-deficient women (14). Previous meta-analyses have endeavored to compare the effects of isoflavone-rich soy preparations on

Supported by grants from the Future Food Innovation; Danish Agency for Science, Technology and Innovation; and the Aase and Ejnar Danielsen's Fund.

The funders had no influence in the design, implementation, analysis, and/or interpretation of the study.

Supplemental Figures 1 and 2 and Supplemental Table 1 are available from the "Online Supporting Material" link in the online posting of the article and from the same link in the online table of contents at <http://ajcn.nutrition.org>.

Address correspondence to PBJ (e-mail: [per.bendix.jeppesen@clin.au.dk](mailto:per.bendix.jeppesen@clin.au.dk)).

Abbreviations used: BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; ER, estrogen receptor; ET, estrogen therapy; RCT, randomized controlled trial; WMD, weighted mean difference.

Received January 16, 2017. Accepted for publication June 27, 2017.

First published online August 2, 2017; doi: <https://doi.org/10.3945/ajcn.116.151464>.

estrogen-deficient bone loss. These analyses show inconsistent and often conflicting results, largely because of high heterogeneity between the study designs of the included RCTs and the majority of these studies do not use methodologies to determine isoflavone content and form (15–17). A key determinant of the efficacy of any bioactive substance is its bioavailability and metabolism in humans. Glycosides have higher molecular weights and hydrophobicity than their aglycone counterparts; hence, conversion to aglycones via deconjugation of glycoside residues by intestinal bacteria and epithelial cells is requisite for passive diffusion of isoflavones into intestinal cells (18). Isoflavones occur predominantly as glycosides in plants, and recent human trials demonstrated isoflavones improved bioavailability when provided as aglycones; hence, aglycones may have improved biological efficacy (19, 20). Food matrix effects may also influence the outcomes of isoflavone RCTs: a recent trial indicated that complex nondigestible dietary fibers fructooligosaccharides may reduce the absorption of dietary isoflavone components, which has implications for RCTs using isoflavone food matrices in treatment arms (21). To our knowledge, there is no systematic review or meta-analysis investigating the effects of isoflavones against estrogen-deficient BMD loss for RCTs providing isoflavone aglycones in treatment arms. This systematic review and meta-analysis was performed to provide an overview of the effects of isoflavone treatments against estrogen-deficient bone resorption in women and to inform researchers of new potential sources of bias to be addressed in future clinical trials.

## METHODS


### Study selection and search strategy

The meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (22). PubMed and EMBASE were searched for RCTs up to December 2016. Key search terms were as follows: isoflavone, genistein, biochanin A, daidzein, formononetin, genistin, daidzin, sissotrin, ononin, bone, bone tissue, osteoporosis, fractures, bone density, bone mineral density, bone resorption, bone degeneration, bone loss, bone remodelling, bone turnover, osteogenesis, bone regeneration, physiologic ossification, bone formation, bone disease, bone metabolism, fracture, bone destruction, osteopenia, absorptiometry, photon absorptiometry, dual-energy X-ray absorptiometry scan, essential osteolysis, climacteric, menopause, pre-menopause, peri-menopause,

post-menopause, menopausal, and estrogen deficiency. Dual-energy X-ray absorptiometry (DXA) is the most tested and used bone density assessment technology. It functions by emitting X-rays with differing energy levels, which are absorbed to varying degrees by human tissues, and BMD is determined by the absorption of the X-ray beams (23, 24). Each term was searched as free terms and in combinations, including the [MESH] terms in PubMed and [EMTREE] versions in EMBASE. Studies were considered eligible for inclusion in the meta-analysis if they met all of the following criteria: RCTs including menopausal or postmenopausal women treated with isoflavones for  $\geq 3$  mo, with the use of DXA as a measurement marker; BMD specified in grams per square centimeter with  $\geq 1$  measurement taken at the femoral neck or lumbar spine; a specified labeled or determined isoflavone dose as aglycones or aglycone equivalents or isoflavones; and reported mean change in BMD from baseline to the end of the study along with corresponding SDs, SEMs, or 95% CIs. Studies were excluded if participants had used hormone therapy or selective estrogen receptor modulator preparations during or  $\leq 3$  mo before initiation of the trial or estimated isoflavone intake was used (i.e., self-report or registry-based data). In cases where stratified data were reported together with total data from the same subject data pool, the largest sample and most detailed data were included in the meta-analysis. Two reviewers independently reviewed and evaluated all article titles and abstracts and thereafter performed independent full-text assessments. A third independent reviewer was consulted in cases where reviewers' evaluations were not in consensus.

### Outcome measures

Outcomes of interest were changes in DXA-determined BMD at the lumbar spine and femoral neck; these were used to determine the effects of isoflavone treatment on bone health compared with control. Second, data from RCTs providing purified isoflavone aglycones to participants were further analyzed separately. As glycoside standards are difficult to acquire, most analytic techniques for determining isoflavone concentration in treatments include an enzymatic or acidic hydrolysis step to convert glycoside species to their respective aglycones. The isoflavone content data are often published as aglycone equivalents and only reflect the total isoflavone content and not actual glycoside or aglycone concentrations. All studies included in the meta-analysis providing soy protein isolates, powders, milk, or soy extracts that did not specify any processing or fermentation steps for their interventions (to convert glycosides to aglycones)



**FIGURE 1** Risk of bias, including the assessment of risk of bias for each item by the authors. Data are shown as percentages for all studies.

were considered by reviewers to be isoflavone glycoside treatments, in line with previous research on soy-based products (25). RCTs that performed assessment of the isoflavone content and form of their interventions that indicated predominantly glycoside concentrations were also considered glycoside interventions (26–28).

**Quality assessment**

The quality of the included studies was assessed with the use of the risk of bias assessment tool outlined in the Cochrane Handbook for Systematic Reviews of Interventions (version 5.3.0) (29). This tool comprises selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome data), attribution bias (incomplete outcome data), reporting bias (selective reporting), and other sources of bias (Figures 1 and 2).

**Statistics**

Meta-analyses were performed, when appropriate, for each DXA site with the 26 included articles. These were then further stratified into RCTs providing isoflavone as aglycones and those treating with isoflavone glycosides. The Revman 5 (Cochrane Information Management System) was used when data were available and trials were considered of sufficient quality. For articles not specifying means or SDs (medians, ranges, or 95% CIs), the correlation coefficient of 0.5 was imputed for calculating the SD of mean change (30). For the articles with no useful data, letters and e-mails were sent to the authors requesting data; if data were still unobtainable, articles were then excluded. The random-effects model was used to calculate weighted mean difference (WMD) and 95% CI, and  $P < 0.05$  was considered statistically significant. Outcomes were assessed by comparing the mean  $\pm$  SD of the BMD change of the isoflavone treatment group with the control group. Heterogeneity between studies was determined with the use of  $I^2$  and the Cochrane  $\chi^2$  statistic:  $I^2$  values of  $\leq 25\%$  were considered low,  $>25\%$  or  $<75\%$  as moderate, and  $\geq 75\%$  as high heterogeneity (29). Funnel plots were used to evaluate publication bias (Supplemental Figures 1 and 2).

**RESULTS**


A total of 1544 articles were identified from the initial search in EMBASE and PubMed. Only the title and abstract were screened in the first selection round, where 124 articles were identified and passed on to the full-text assessment. Of the 124 articles, there were a total of 51 duplicates, 5 abstract-only articles (published at congresses and conferences), 3 articles that shared the same participants as other studies, and 39 others that did not meet all the inclusion criteria. All trials were RCTs. After removing duplicates and congress papers, 73 papers were eligible and systematically assessed for inclusion. Twenty-six RCTs met the inclusion criteria and were used in the meta-analysis (26–28, 31–53). A detailed overview of the selection process is outlined in Figure 3.

The included studies varied substantially in duration; 9 were 24 mo long, 6 were 6 mo long, 2 spanned 3 mo, and only 1 study was 15 mo in duration. Five studies included 2 treatment arms with different isoflavone doses; these arms were considered

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Alekel 2000 (4.4mg) (50)	?	+	?	?	+	+	?
Alekel 2000 (80.4mg) (50)	?	+	?	?	+	+	?
Atkinson 2004 (47)	+	+	+	+	+	+	?
Atteritano 2009 (88)	?	?	?	?	+	+	?
Chen J 2014 (33)	?	+	+	?	+	+	?
Chen Y 2004 (40mg) (100)	+	+	+	+	+	+	?
Chen Y 2004 (80mg) (100)	+	+	+	+	+	+	?
Chilibeck 2013 (34)	+	+	+	+	+	+	?
Choquette 2011 (37)	?	?	?	?	+	+	?
Clifton-Bligh 2015 (32)	?	?	+	+	+	+	?
Dong 2008 (39)	?	?	+	+	+	+	?
Harkness 2004 (44)	+	+	?	?	+	+	?
Huang 2006 ( 100 mg) (43)	?	+	+	+	+	+	?
Huang 2006 ( 200 mg) (43)	?	+	+	+	+	+	?
Kenny 2009 (52)	?	?	?	?	+	+	?
Kreijkamp-Kaspers 2004 (46)	+	+	+	+	+	+	?
Levis 2011 (36)	?	+	+	+	+	+	?
Lydeking-Olsen 2004 (45)	?	+	+	+	+	+	?
Marini 2007 (40)	+	+	?	?	+	+	?
Morabito 2002 (53)	?	+	?	?	+	+	?
Newton 2006 (51)	?	?	?	?	+	+	?
Potter 1998 (56mg) (49)	?	+	?	?	+	+	?
Potter 1998 (90mg) (49)	?	+	?	?	+	+	?
Radhakrishnan 2009 (26)	+	+	+	+	+	+	?
Tai 2012 (35)	?	+	?	?	+	+	?
Thorup 2015 (31)	+	+	+	+	+	+	?
Uesugi 2003 (27)	?	?	?	?	+	+	?
Vupadhyayula 2009 (38)	+	+	+	+	+	+	?
Wu 2006 (86)	?	?	?	?	+	+	?
Ye 2006 (126mg) (42)	+	+	?	?	+	+	?
Ye 2006 (84mg) (42)	+	+	?	?	+	+	?
Zhang 2007 (41)	+	+	?	?	+	+	?

**FIGURE 2** Risk of bias summary for each study as determined by the judgments of the authors.

separately in the analysis (42, 43, 48–50). All 26 RCTs provided BMD data from DXA scans at the lumbar spine (26–28, 31–53). Fifteen of the studies also provided DXA data for femoral neck BMD (28, 31, 32, 34, 36–43, 48, 53). Of the 26 RCTs (26–28, 31–53) providing data at the lumbar spine, 6 studies (31, 40, 41, 44, 47, 53) found substantial improvements to BMD with



**FIGURE 3** A flow diagram presenting the number of randomized controlled trials that were screened and assessed for eligibility, and the number included in the final meta-analysis.

isoflavone treatment. Four (31, 40, 41, 53) of the 15 RCTs (28, 31, 32, 34, 36–43, 48, 53) demonstrated substantial effects on BMD at the femoral neck.

### Quality of the studies

None of the studies reported any relevant intergroup differences in the baseline characteristics of the intervention and control groups. Apart from 3 of the RCTs (33, 39, 43), all other included trials, to various degrees, described measures for blinding of participants and personnel taking part in the studies (33, 39, 43). Two of the aforementioned RCTs did not indicate any measures for blinding of outcome assessment (39, 43).

### Participants

A total of 2652 participants were included in the final analysis from the 26 RCTs (Table 1). The majority of the RCTs included postmenopausal participants, which totaled 18 (26, 28, 33–35, 37–41, 43–46, 48, 49, 51, 52). Four of the studies included exclusively perimenopausal women (31, 32, 36, 50). Four studies mixed both participant types (27, 42, 47, 53). One study included both male and female participants, but only data from women included in this study was included in the meta-analysis (51).

### Interventions

Two trials compared an extract rich in isoflavones against the control (27, 31). Two RCTs administered red clover–derived isoflavone tablets compared with placebo tablets (32, 47). Eight studies used isoflavones isolated from soy in the treatment arm compared with soy protein alone or placebo (35, 36, 39, 42–44, 46, 48). One trial tested isoflavone-enriched food matrices (particularly soymilk) comparing against isoflavone-free equivalents in the control arms (45). Lydeking-Olsen et al. (45) performed an analysis of the soy milk isoflavone contents specifying

aglycones; however, the analytic procedure included an enzymatic hydrolysis step, and the treatment was therefore considered to be glycoside based. Five assessed soy protein isolate against control (26, 38, 49–51). Three administered isoflavone equivalents compared with placebo (33, 34, 52). Four RCTs compared intake of tablets with purified isoflavones (genistein, daidzein, and glycitein) against placebo tablets (37, 40, 41, 53). One study investigated the isoflavone conjugates (genistin, daidzin, daidzin, acetyldaidzin, genistin, and glycitin), comparing with isoflavone-free dextrin placebo capsules (28).

### Meta-analysis

#### Lumbar spine BMD

The effects of isoflavone treatments against BMD loss at the lumbar spine in estrogen-deficient women are shown in Figure 4. Data from all 26 studies were pooled and analyzed, and results indicated a significant ( $P < 0.00001$ ) improvement in estrogen-deficient BMD loss in participants given daily isoflavone treatment compared with controls, with a WMD favoring isoflavone of  $0.01 \text{ g/cm}^2$  (95% CI: 0.01, 0.02  $\text{g/cm}^2$ ;  $I^2$ , 90%) (26–28, 31–53). Subgroup analysis results for studies used to assess isoflavone effects on lumbar BMD are shown in Supplemental Table 1.

#### Femoral neck BMD

The effects of isoflavone treatments for reducing estrogen-deficient BMD loss at the femoral neck in women for the 15 RCTs are displayed in Figure 5. Analysis of the femoral neck data comparing isoflavone and control showed a significant ( $P < 0.01$ ) reduction of BMD loss in isoflavone groups in contrast to the control (WMD favoring isoflavone of  $0.01 \text{ g/cm}^2$ ; 95% CI: 0.00, 0.02  $\text{g/cm}^2$ ;  $I^2$ , 90%). Subgroup analysis results for studies used to determine isoflavone effects on femoral neck BMD are presented Supplemental Table 1.

**TABLE 1**  
Summary of included studies<sup>1</sup>

Study, year (ref)	Trial length	n (I/C)	Intervention	IS (dose, mg; form, Agl, Eq, Gly)	Age, y	Status	DXA site
Thorup et al., 2015 (31)	3 mo	31/29	I: 150 mL RC extract C: Placebo	37.1; Agl	40–65	Peri	LS, FN
Clifton-Bligh et al., 2015 (32)	24 mo	55/42	I: 2 RC tablets C: Placebo	50; Eq	50–58	Peri	LS, FN
Chilibeck et al., 2013 (34)	24 mo	76/73	I: Exercise placebo + IS C: Exercise placebo + IS placebo	165; Eq	Mean: 56	Post	LS, TH
Tai et al., 2012 (35)	24 mo	200/199	I: SI C: Placebo	300; Eq	45–65	Post	LS, TH
Levis et al., 2011 (36)	24 mo	97/80	I: SI tablets C: Placebo	200; Eq	45–60	Peri	LS, FN, TH
Vupadhyayula et al., 2009 (38)	24 mo	57/48	I: SP + IS C: SP isolate	90; Eq	>55	Post	LS, FN, TH
Dong et al., 2008 (39)	12 mo	26/26	I: Ca + SI C: Ca	100; Eq	45–65	Post	LS, FN
Marini et al., 2008 (54)	24 mo	150/154	I: GE C: Placebo	54; Agl	51–56	Post	LS, FN
Ye et al., 2006 (84 mg) (42)	6 mo	28/30	I: SI C: Placebo	84; Eq	45–60	Peri and post	LS, FN, TH
Ye et al., 2006 (126 mg) (42)	6 mo	26/30	I: SI C: Placebo	126; Eq	45–60	Peri and post	LS, FN, TH
Wu et al., 2006 (28)	6 mo	33/33	I: IS conjugate C: Placebo	75; Gly	45–60	Post	LS, FN, TH
Harkness et al., 2004 (44)	6 mo	10/9	I: SI C: Placebo	110; Eq	64–76	Post	LS, TH
Atkinson et al., 2004 (47)	12 mo	77/81	I: RC IS C: Placebo	43.5; Agl	49–65	Peri and post	LS
Chen et al., 2003 (40 mg) (48)	12 mo	57/53	I: SI C: Placebo	40; Eq	48–62	Post	LS, FN, TH
Chen et al., 2003 (80 mg) (48)	12 mo	50/53	I: SI C: Placebo	80; Eq	48–62	Post	LS, FN, TH
Kenny et al., 2009 (52)	12 mo	26/22	I: CP + IS tablets C: CP + placebo tablets	105; Eq	60–93	Post	LS, FN, TH
Newton et al., 2006 (51)	12 mo	9/7	I: SP + 83 mg IS C: SP + 3 mg IS	83; Eq	50–80	Post	LS, TH
Chen and Liu, 2014 (33)	12 mo	40/30	I: MP + IS C: Normal diet	70; Eq	50–70	Post	LS
Alekel et al., 2000 (80.4 mg) (50)	24 wk	24/21	I: SP + IS C: Whey	80.4; Eq	44.7–59.4	Peri	LS
Alekel et al., 2000 (4.4 mg) (50)	24 wk	24/21	I: SP + IS C: Whey	4.4; Eq	41.9–61.6	Peri	LS
Choquette et al., 2011 (37)	6 mo	23/22	I: DE + GE + glycitein C: Placebo	70; Eq	50–70	Post	LS, FN, TH
Zhang et al., 2007 (41)	24 mo	50/50	I: DE + GE + icariin C: Placebo	78; Agl	60–68	Post	LS, FN
Huang et al., 2006 (100 mg) (43)	12 mo	15/12	I: SI C: Placebo	100; Eq	45–67	Post	LS, FN
Huang et al., 2006 (200 mg) (43)	12 mo	15/12	I: SI C: Placebo	200; Eq	45–67	Post	LS, FN
Lydeking-Olsen et al., 2004 (45)	24 mo	23/22	I: IS-rich soymilk C: IS-poor soymilk	76; Eq	50–75	Post	LS
Kreijkamp-Kaspers et al., 2004 (46)	12 mo	88/87	I: IS-rich SP C: MP	99; Eq	60–75	Post	LS, TH
Uesugi et al., 2003 (27)	3 mo	11/10	I: IS extract C: Placebo	61.8; Gly	45–65	Peri and post	LS
Potter et al., 1998 (56 mg) (49)	6 mo	22/22	I: SP + IS C: Casein + nonfat dry milk	56; Eq	49–73	Post	LS

(Continued)

TABLE 1 (Continued)

Study, year (ref)	Trial length	n (I/C)	Intervention	IS (dose, mg; form, Agl, Eq, Gly)	Age, y	Status	DXA site
Potter et al., 1998 (90 mg) (49)	6 mo	22/22	I: SP + IS C: Casein + nonfat dry milk	90; Eq	39–83	Post	LS
Radhakrishnan et al., 2009 (26)	6 mo	44/41	I: SP + IS C: Casein protein	75; Gly	Mean: 49	Post	LS
Morabito et al., 2002 (53)	12 mo	30/30	I: GE C: Placebo	54; Agl	47–57	Peri and post	LS, FN

<sup>1</sup> Agl, aglycone; C, control group; CP, control protein; DE, daidzein; DXA, dual-energy X-ray absorptiometry; Eq, aglycone equivalents; FN, femoral neck; GE, genistein; Gly, glycoside; I, intervention group; IS, isoflavone; LS, lumbar spine; MP, milk protein; Peri, perioperative; Post, postoperative; RC, red clover; ref, reference; SI, soy isoflavone; SP, soy protein; TH, total hip.

#### Assessment of RCTs determining isoflavone content

An assessment of the 5 articles with a given isoflavone aglycone content of interventions compared with the control was performed. When isolating the results of these RCTs, a substantial beneficial effect was found for both the BMD change outcomes for the lumbar spine (Figure 6) and femoral neck (Figure 7) in favor of the isoflavone treatment compared with the control. The 5 studies in the pool providing data of the lumbar spine yielded a significant ( $P < 0.00001$ ) effect of isoflavone intake against BMD loss compared with the control, showing the following WMD of BMD change favoring isoflavone: 0.04 g/cm<sup>2</sup> (95% CI: 0.02, 0.05 g/cm<sup>2</sup>;  $I^2$ , 98%) (31, 40,

41, 47, 53). For the femoral neck, a significant ( $P < 0.05$ ) beneficial effect of isoflavone treatment was found in the 4 studies providing BMD data at the femoral neck and assessing isoflavone content, with the following WMD of BMD change favoring isoflavone: 0.03 g/cm<sup>2</sup> (95% CI: 0.00, 0.06 g/cm<sup>2</sup>;  $I^2$ , 98%) (31, 40, 41, 53).

#### Studies excluded from the meta-analysis

A total of 47 RCTs were excluded from the meta-analysis during the full-text assessment. Fifteen original articles were excluded for not having an isoflavone intervention arm (there was prevalent use of self-report methods for estimating isoflavone





FIGURE 4 Forest plot showing the difference in bone mineral density change at the lumbar spine in all trials ( $n = 26$ ) between isoflavone-administered and control groups. Data calculated from the random-effects model are presented as weighted mean difference and 95% CI. IV, inverse variance.



**FIGURE 5** Forest plot showing the difference in bone mineral density change at the femoral neck in all trials between isoflavone-administered and control groups (*n* = 15). Data calculated from the random-effects model are presented as weighted mean difference and 95% CI. IV, inverse variance.


intake) (55–69). Twelve studies were excluded because their study designs were not in line with other aspects of the inclusion criteria (70–81). Twelve RCTs did not provide usable data (i.e., publishing BMD as a percentage, showing BMD changes only graphically, only showing start and end BMD, or taking BMD measurements at other skeletal sites or not with the use of only bone turnover biomarkers) (82–93). Five of the articles were published as congress or conference abstracts without full texts (94–98). Three trials were substudies of other trials already included in the meta-analysis (54, 99, 100).

**DISCUSSION**


This review provides evidence that isoflavone supplementation can blunt estrogen-deficient BMD resorption on peri- and postmenopausal women. Overall, an equivalent attenuative effect was found for isoflavone treatment on BMD loss at the lumbar spine (0.01 g/cm<sup>2</sup>) compared with the femoral neck (WMD: 0.01 g/cm<sup>2</sup>). The higher efficacy of isoflavone treatment at the lumbar spine could be attributed to a number of factors. It may be caused by differences in bone tissue composition between these sites, with trabecular (spongy) bone comprising a greater proportion of the bone tissue at the lumbar spine in contrast to the femoral neck, which incorporates a higher proportion of

dense cortical bone tissue (101). Trabecular bone offers a larger surface area, allowing for greater accessibility for estrogenic agents. The affinity of isoflavones for ERβ could also contribute to the enhanced effects at trabecular bone sites, as trabecular and cortical bone retain differential expression profiles of ER isoforms, where trabecular bone retains a higher expression of ERβ:ERα than cortical-rich bone sites that have expressed ERα to a greater extent (102).

The outcomes of other meta-analyses investigating the effects of isoflavones on bone remain inconsistent and controversial. This is most likely due to the high heterogeneity of RCTs in this field of research. One of the most prevalent sources of bias for this group of papers was differences in formulations and the apparent lack of RCTs that use methodologies for validation and standardization of isoflavone content and isoflavone form (methylated forms, glycosides, and aglycones). Research has consistently shown that commercial isoflavone preparations have highly variable isoflavone contents and often do not contain the corresponding isoflavone concentrations or forms claimed on the label (103–105). This represents a key source of bias when all 26 articles are pooled. The present meta-analysis found that RCTs using interventions with a well-controlled isoflavone content and providing isoflavones as aglycones tended to attain enhanced beneficial effect sizes against estrogen-deficient BMD resorption



**FIGURE 6** Forest plot showing the difference in bone mineral density change at the lumbar spine in studies providing isoflavone aglycones (*n* = 5) to treatment compared with control. Data calculated from the random-effects model are presented as weighted mean difference and 95% CI. IV, inverse variance.



**FIGURE 7** Forest plot showing the difference in bone mineral density change at the femoral neck in studies providing isoflavone aglycones ( $n = 4$ ) to treatment compared with control. Data calculated from the random-effects model are presented as weighted mean difference and 95% CI. IV, inverse variance.

at both the femoral neck (mean difference:  $0.04 \text{ g/cm}^2$ ) and lumbar spine (mean difference:  $0.03 \text{ g/cm}^2$ ) in women compared with RCTs that did not. This both supports and underlines the importance for future RCTs investigating isoflavone and bone health to use higher-quality methods to analyze the contents of test preparations before initiating studies. It is important to consider that there were a limited number of RCTs that actually provided isoflavone aglycones (5); if a greater number of RCTs with determined aglycone content were available, it would go further to confirm these findings. Intestinal isoflavone uptake is dependent on passive diffusion, and isoflavone glycosides require hydrolytic conversion to aglycones to be absorbed; hence, aglycones may have improved bioavailability and thereby enhanced biological efficacy (106). A meta-analysis by Dören (107) found that 2-y treatment with various estrogen therapies exerted equivalent mean improvements to BMD at the spine relative to placebo of  $\sim 6.71\%$ . Considering that the mean BMD for women across the menopausal transition has been shown to be  $\sim 1.07 \text{ g/cm}^2$  for the lumbar spine, this represents a BMD improvement relative to placebo in the average range of  $\sim 0.072 \text{ g/cm}^2$  (3). A reduction of 1 SD in femoral neck BMD has been associated with an increased fracture risk ratio of 2.88 in elderly women ( $\geq 65$  y). Elderly women have also been demonstrated to retain a mean  $\pm$  SD femoral neck BMD of  $0.72 \pm 0.11$  (108, 109). As such, the relative BMD increases found in the present meta-analysis of  $0.04 \text{ g/cm}^2$  at the spine and  $0.03 \text{ g/cm}^2$  at the femoral neck can be considered clinically relevant.

The present meta-analysis supports that isoflavone form appears to be an often-unaccounted for confounding factor that affects many of the current RCTs investigating isoflavones and bone health in women. This may also contribute to the conflicting and inconsistent results of previous meta-analyses (15–17).

There was a high heterogeneity in all of the data pools, with  $I^2$  values ranging from 90% to 98%, leading to the choice of the random-effects model in this analysis. The high  $I^2$  values indicate that the studies substantially differed. Indeed, the findings from the present meta-analysis must be critically interpreted because of the limited number of studies and the great discrepancies in their design. There were substantial confounders across all the RCTs within this meta-analysis. Interventions varied substantially in terms of dose (4.4–300 mg) and the reported molecular form of isoflavones given; these ranged from aglycone equivalents, reporting concentrations for specific isoflavones, to only specifying isoflavone concentration without stating which isoflavone species were included. In some cases, interventions were combined with other components that may influence bone health such as exercise, micronutrient supplementation,

and soy and milk proteins. The duration of all studies ranged from 3 to 15 mo; therefore, considering that the bone remodeling cycle lasts  $\sim 4$ –8 mo, longer study durations would be more relevant for determining BMD changes (110). The characterization of participants in the RCTs may also introduce confounding to the current meta-analysis, as peri- and postmenopausal women have differing rates of estrogen-deficient bone loss and may respond differently to estrogenic therapies, with the former losing 2–5% BMD/y and the latter losing 1–2% BMD/y (3, 4). A few RCTs within the analysis did not report blinding of participants or blinding of outcome assessor. All of these factors contribute to the high heterogeneity and confounding. Other differences between the studies were menopause status (definition and determination of peri- and postmenopause); including either peri- or postmenopausal participants alone or mixed; the number of participants (ranging from 16 to 399); and dosing strategies (with or without meal, single dose in the morning or twice daily in the morning and evening). Oral isoflavone supplements have been shown to retain a plasma half-life of 4–8 h, and a twice-daily dose with a meal may have improved efficacy that a single daily dose (103).

This meta-analysis supports the statement that a greater number of longer-duration, high-quality RCTs that use analytic methods to ensure isoflavone concentration with defined molecular forms are required to further elucidate the effects of isoflavone treatments on BMD in women, particularly with regard to isoflavone aglycones. Moreover, the evidence provided by this meta-analysis would be strengthened by RCTs that have more standardized and rigorous study designs. The systematic review identified 10 otherwise useful RCTs that were unable to be included as they opted to publish their BMD results in an unsuitable fashion, often as percentiles, ranges, or medians (rather than mean differences); by only presenting certain data graphically; or by providing only start and end values without specifying the absolute change. These inconsistencies in the publishing of data present a challenge to authors seeking to include RCTs in meta-analyses and inevitably results in smaller data pools and data loss.

In conclusion, our systematic review of existing literature of isoflavone treatments against estrogen-deficient bone loss in women suggests that isoflavone treatments can be effective in preserving BMD and attenuating accelerated bone resorption. In particular, our review emphasizes that RCTs using isoflavone aglycones with well-controlled, standardized, and defined isoflavone interventions appear to achieve greater efficacy when used to treat BMD loss in estrogen-deficient women compared with glycosides and less well-defined isoflavone formulations. Only isoflavone aglycones showed potency against BMD loss; as such,



aglycone content may represent a key factor influencing the outcomes of many RCTs focused on treating bone health in estrogen deficiency.

We thank the Aarhus State Library and in particular librarian Maria Østerbye for her expertise in structured systematic literature search methods for the current article.

The authors' responsibilities were as follows—MNTL: wrote and took primary responsibility for the final content of the manuscript; MNTL and LMH: undertook the data collection and performed the statistical analyses; MNTL and PBJ: revised the manuscript; and all authors: designed the research, interpreted the analyses, and read and approved the final manuscript. None of the authors reported a conflict of interest related to the study.

## REFERENCES

- Papioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ* 2010;182:1864–73.
- Bonnick SL. Osteoporosis in men and women. *Clin Cornerstone* 2006;8:28–39.
- Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, Lo JC, Johnston JM, Cauley JA, Danielson ME, et al. Bone mineral density changes during the menopause transition in a multi-ethnic cohort of women. *J Clin Endocrinol Metab* 2008;93:861–8.
- Moilanen J, Aalto A-M, Hemminki E, Aro AR, Raitanen J, Luoto R. Prevalence of menopause symptoms and their association with lifestyle among Finnish middle-aged women. *Maturitas* 2010;67:368–74.
- Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women's health initiative randomized trial. *JAMA* 2003;290:1729–38.
- Michael YL, Gold R, Manson JE, Keast EM, Cochrane BB, Woods NF, Brzyski RG, McNeeley SG, Wallace RB. Hormone therapy and physical function change among older women in the Women's Health Initiative: a randomized controlled trial. *Menopause* 2010;17:295–302.
- Khalid AB, Krum SA. Estrogen receptors alpha and beta in bone. *Bone*. 2016;87:130–5.
- Yue W, Yager JD, Wang J-P, Jupe ER, Santen RJ. Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. *Steroids* 2013;78:161–70.
- Bowring CE, Francis RM. National Osteoporosis Society's position statement on hormone replacement therapy in the prevention and treatment of osteoporosis. *Menopause Int* 2011;17:63–5.
- Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* 1997;389:753–8.
- Burns KA, Korach KS. Estrogen receptors and human disease: an update. *Arch Toxicol* 2012;86:1491–504.
- Spagnuolo P, Rasini E, Luini A, Legnaro M, Luzzani M, Casareto E, Carreri M, Paracchini S, Marino F, Cosentino M. Isoflavone content and estrogenic activity of different batches of red clover (*Trifolium pratense* L.) extracts: an in vitro study in MCF-7 cells. *Fitoterapia* 2014;94:62–9.
- Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, et al. Estrogen receptors: how do they signal and what are their targets. *Physiol Rev* 2007;87:905–31.
- Coxam V. Phyto-oestrogens and bone health. *Proc Nutr Soc* 2008;67:184–95.
- Liu J, Ho SC, Su Y, Chen W, Zhang C, Chen Y. Effect of long-term intervention of soy isoflavones on bone mineral density in women: a meta-analysis of randomized controlled trials. *Bone* 2009;44:948–53.
- Ma D-F, Qin L-Q, Wang P-Y, Katoh R. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. *Eur J Clin Nutr* 2008;62:155–61.
- Taku K, Melby MK, Takebayashi J, Mizuno S, Ishimi Y, Omori T, Watanabe S. Effect of soy isoflavone extract supplements on bone mineral density in menopausal women: meta-analysis of randomized controlled trials. *Asia Pac J Clin Nutr* 2010;19:33–42.
- Islam MA, Punt A, Spenkelink B, Murk AJ, Rolaf van Leeuwen FX, Rietjens IMCM. Conversion of major soy isoflavone glucosides and aglycones in in vitro intestinal models. *Mol Nutr Food Res* 2014;58:503–15.
- Okabe Y, Shimazu T, Tanimoto H. Higher bioavailability of isoflavones after a single ingestion of aglycone-rich fermented soybeans compared with glucoside-rich non-fermented soybeans in Japanese postmenopausal women. *J Sci Food Agric* 2011;91:658–63.
- Miura A, Sugiyama C, Sakakibara H, Simoi K, Goda T. Bioavailability of isoflavones from soy products in equal producers and non-producers in Japanese women. *J Nutr Intermed Metab*. 2016;6:41–7.
- Lipovac M, Pfitscher A, Hobiger S, Laschitz T, Imhof M, Chedraui P, Jungbauer A. Red clover isoflavone metabolite bioavailability is decreased after fructooligosaccharide supplementation. *Fitoterapia* 2015;105:93–101.
- Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
- Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. *Am J Clin Nutr* 1990;51:1106–12.
- Lewiecki EM, Binkley N, Morgan SL, Shuhart CR, Camargos BM, Carey JJ, Gordon CM, Jankowski LG, Lee J-K, Leslie WD; International Society for Clinical Densitometry. Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry guidance. *J Clin Densitom* 2016;19:127–40.
- Wang H, Murphy PA. Isoflavone content in commercial soybean foods. *J Agric Food Chem* 1994;42:1666–73.
- Radhakrishnan G, Rashmi, Agarwal N, Vaid NB. Evaluation of isoflavone rich soy protein supplementation for postmenopausal therapy. *Pak J Nutr* 2009;8:1009–17.
- Uesugi T, Toda T, Okuhira T, Chen J-T. Evidence of estrogenic effect by the three-month-intervention of isoflavone on vaginal maturation and bone metabolism in early postmenopausal women. *Endocr J* 2003;50:613–9.
- Wu J, Oka J, Higuchi M, Tabata I, Toda T, Fujioka M, Fuku N, Teramoto T, Okuhira T, Ueno T, et al. Cooperative effects of isoflavones and exercise on bone and lipid metabolism in postmenopausal Japanese women: a randomized placebo-controlled trial. *Metabolism* 2006;55:423–33.
- Higgins JPT, Green S, editors. *Cochrane handbook for systematic reviews of interventions*. Version 5.1.0. Chapter 16.4.5: Methods for incorporating cross-over trials into a meta-analysis [updated March 2011]. The Cochrane Collaboration; 2011. [cited 2016 Sep 20]. Available from: [http://handbook.cochrane.org/chapter\\_16/16\\_4\\_5\\_methods\\_for\\_incorporating\\_cross\\_over\\_trials\\_into\\_a.htm](http://handbook.cochrane.org/chapter_16/16_4_5_methods_for_incorporating_cross_over_trials_into_a.htm).
- Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* 2005;5:13.
- Thorup AC, Lambert MN, Kahr HS, Bjerre M, Jeppesen PB. Intake of novel red clover supplementation for 12 weeks improves bone status in healthy menopausal women. Evidence-Based Complement Altern Med 2015;2015: 689138 .
- Clifton-Bligh PB, Nery M-L, Clifton-Bligh RJ, Visvalingam S, Fulcher GR, Byth K, Baber R. Red clover isoflavones enriched with formononetin lower serum LDL cholesterol—a randomized, double-blind, placebo-controlled study. *Eur J Clin Nutr* 2015;69:134–42.
- Chen J, Liu X. Effects on blood fat and bone density of postmenopausal women fed by soy protein with isoflavone. *Zhonghua Yi Xue Za Zhi* 2014;94:215–7.
- Chilibeck PD, Vatanparast H, Pierson R, Case A, Olatunbosun O, Whiting SJ, Beck TJ, Pahwa P, Biem HJ. Effect of exercise training combined with isoflavone supplementation on bone and lipids in postmenopausal women: a randomized clinical trial. *J Bone Miner Res* 2013;28:780–93.

35. Tai TY, Tsai KS, Tu ST, Wu JS, Chang CI, Chen CL, Shaw NS, Peng HY, Wang SY, Wu CH. The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study. *Osteoporos Int* 2012;23:1571–80.
36. Levis S, Strickman-Stein N, Ganjei-Azar P, Xu P, Doerge DR, Krischer J. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. *Arch Intern Med* 2011;171:1363–9.
37. Choquette S, Riesco É, Cormier É, Dion T, Aubertin-Leheudre M, Dionne IJ. Effects of soya isoflavones and exercise on body composition and clinical risk factors of cardiovascular diseases in overweight postmenopausal women: a 6-month double-blind controlled trial. *Br J Nutr* 2011;105:1199–209.
38. Vupadhyayula PM, Gallagher JC, Templin T, Logsdon SM, Smith LM. Effects of soy protein isolate on bone mineral density and physical performance indices in postmenopausal women—a 2-year randomized, double-blind, placebo-controlled trial. *Menopause* 2009;16:320–8.
39. Dong J, Huang ZW, Piao JH, Li F, Zeng J, Gong J, Yang XG. Relationship between estrogen receptor gene P<sub>x</sub> haplotype and the effect of calcium and soy isoflavone supplementation on bone mineral density of Chinese postmenopausal women. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2008;42:329–34.
40. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, Gaudio A, Mazzaferro S, Frisina A, Frisina N, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. *Ann Intern Med* 2007;146:839–47.
41. Zhang G, Qin L, Shi Y. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. *J Bone Miner Res* 2007;22:1072–9.
42. Ye Y-B, Tang X-Y, Verbruggen MA, Su Y-X. Soy isoflavones attenuate bone loss in early postmenopausal Chinese women: a single-blind randomized, placebo-controlled trial. *Eur J Nutr* 2006;45:327–34.
43. Huang H-Y, Yang H-P, Yang H-T, Yang T-C, Shieh M-J, Huang S-Y. One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. *J Nutr Biochem* 2006;17:509–17.
44. Harkness LS, Fiedler K, Sehgal AR, Oravec D, Lerner E. Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. *J Womens Health (Larchmt)* 2004;13:1000–7.
45. Lydeking-Olsen E, Beck-Jensen JE, Setchell KDR, Holm-Jensen T. Soy milk or progesterone for prevention of bone loss: a 2 year randomized, placebo-controlled trial. *Eur J Nutr* 2004;43:246–57.
46. Krejlikamp-Kaspers S, Kok L, Grobbee DE, de Haan EHF, Aleman A, Lampe JW, van der Schouw YT. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. *JAMA* 2004;292:65–74.
47. Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. *Am J Clin Nutr* 2004;79:326–33.
48. Chen Y-M, Ho SC, Lam SSH, Ho SSS, Woo JLF. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. *J Clin Endocrinol Metab* 2003;88:4740–7.
49. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. *Am J Clin Nutr* 1998;68:1375S–9S.
50. Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. *Am J Clin Nutr* 2000;72:844–52.
51. Newton KM, LaCroix AZ, Levy L, Li SS, Qu P, Potter JD, Lampe JW. Soy protein and bone mineral density in older men and women: a randomized trial. *Maturitas* 2006;55:270–7.
52. Kenny AM, Mangano KM, Abourizk RH, Bruno RS, Anamani DE, Kleppinger A, Walsh SJ, Prestwood KM, Kerstetter JE. Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial. *Am J Clin Nutr* 2009;90:234–42.
53. Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, D'Anna R, Corrado F, Pizzoleo MA, Cincotta M, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. *J Bone Miner Res* 2002;17:1904–12.
54. Marini H, Bitto A, Altavilla D, Burnett BP, Polito F, Di Stefano V, Minutoli L, Atteritano M, Levy RM, D'Anna R, et al. Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. *J Clin Endocrinol Metab* 2008;93:4787–96.
55. Baglia ML, Gu K, Zhang X, Zheng Y, Peng P, Cai H, Bao P-P, Zheng W, Lu W, Shu X-O. Soy isoflavone intake and bone mineral density in breast cancer survivors. *Cancer Causes Control* 2015;26:571–80.
56. Greendale GA, Tseng C-H, Han W, Huang M-H, Leung K, Crawford S, Gold EB, Waetjen LE, Karlamangla AS. Dietary isoflavones and bone mineral density during midlife and the menopausal transition: cross-sectional and longitudinal results from the Study of Women's Health Across the Nation Phytoestrogen Study. *Menopause* 2015;22:279–88.
57. Kuhnle GGC, Ward HA, Vogiatzoglou A, Luben RN, Mulligan A, Wareham NJ, Forouhi NG, Khaw K-T. Association between dietary phyto-oestrogens and bone density in men and postmenopausal women. *Br J Nutr* 2011;106:1063–9.
58. Ikeda Y, Iki M, Morita A, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H. Intake of fermented soybeans, natto, is associated with reduced bone loss in postmenopausal women: Japanese Population-Based Osteoporosis (JPOS) Study. *J Nutr* 2006;136:1323–8.
59. Chiechi LM, Secreto G, D'Amore M, Fanelli M, Venturelli E, Cantatore F, Valerio T, Laselva G, Loizzi P. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial. *Maturitas* 2002;42:295–300.
60. Dalais FS, Rice GE, Wahlqvist ML, Grehan M, Murkies AL, Medley G, Aytton R, Strauss BJ. Effects of dietary phytoestrogens in postmenopausal women. *Climacteric* 1998;1:124–9.
61. Cook A, Pennington G. Phytoestrogen and multiple vitamin/mineral effects on bone mineral density in early postmenopausal women: a pilot study. *J Womens Health Gend Based Med* 2002;11:53–60.
62. Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. *J Clin Endocrinol Metab* 2001;86:5217–21.
63. Ho SC, Chan SG, Yi Q, Wong E, Leung PC. Soy intake and the maintenance of peak bone mass in Hong Kong Chinese women. *J Bone Miner Res* 2001;16:1363–9.
64. Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. *Obstet Gynecol* 2001;97:109–15.
65. Di Leo C, Tarolo GL, Bestetti A, Tagliabue L, Del Sole A, Aliberti G, Cestaro B, Pepe L. Osteoporosis and phytoestrogens: an assessment of bone mineral density via quantitative peripheral computed tomography in milk-egg-vegetarian women in the premenopause. *Radiol Med (Torino)* 2000;99:250–7.
66. Ho SC, Woo J, Lam S, Chen Y, Sham A, Lau J. Soy protein consumption and bone mass in early postmenopausal Chinese women. *Osteoporos Int* 2003;14:835–42.
67. Nagata C, Shimizu H, Takami R, Hayashi M, Takeda N, Yasuda K. Soy product intake and serum isoflavonoid and estradiol concentrations in relation to bone mineral density in postmenopausal Japanese women. *Osteoporos Int* 2002;13:200–4.
68. Kritiz-Silverstein D, Goodman-Gruen DL. Usual dietary isoflavone intake, bone mineral density, and bone metabolism in postmenopausal women. *J Womens Health Gend Based Med* 2002;11:69–78.
69. Guthrie JR, Ball M, Murkies A, Dennerstein L. Dietary phytoestrogen intake in mid-life Australian-born women: relationship to health variables. *Climacteric* 2000;3:254–61.
70. Chi X-X, Zhang T. The effects of soy isoflavone on bone density in north region of climacteric Chinese women. *J Clin Biochem Nutr* 2013;53:102–7.
71. Atkinson C, Newton KM, Yong M, Stanczyk FZ, Westerlind KC, Li L, Lampe JW. Daidzein-metabolizing phenotypes in relation to bone density and body composition among premenopausal women in the United States. *Metabolism* 2012;61:1678–82.

72. García-Martín A, Quesada Charneco M, Álvarez Guisado A, Jiménez Moleón JJ, Fonollá Joya J, Muñoz-Torres M. Effect of milk product with soy isoflavones on quality of life and bone metabolism in postmenopausal Spanish women: randomized trial. *Med Clin (Barc)* 2012;138:47–51.
73. Wu J, Oka J, Ezaki J, Ohtomo T, Ueno T, Uchiyama S, Toda T, Uehara M, Ishimi Y. Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women. *Menopause* 2007;14:866–74.
74. Frankenfeld CL, McTiernan A, Thomas WK, LaCroix K, McVarish L, Holt VL, Schwartz SM, Lampe JW. Postmenopausal bone mineral density in relation to soy isoflavone-metabolizing phenotypes. *Maturitas* 2006;53:315–24.
75. Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. *Menopause* 2001;8:259–65.
76. Hsu CS, Shen WW, Hsueh YM, Yeh SL. Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density. *J Reprod Med* 2001;46:221–6.
77. Savoca S, D'Agosta S, Tomaselli TG. The effects of soy isoflavones on vasomotor symptoms and bone mineral density in climacteric women. *G Ital di Ostet e Ginecol* 2007;219:143–5.
78. Horiuchi T, Onouchi T. Relationship between urinary phytoestrogen levels and Z score of lumbar vertebral bone mineral density in Japanese postmenopausal women. *Nutr Res* 2006;26:409–12.
79. Kim MK, Chung BC, Yu VY, Nam JH, Lee HC, Huh KB, Lim SK. Relationships of urinary phyto-estrogen excretion to BMD in postmenopausal women. *Clin Endocrinol (Oxf)* 2002;56:321–8.
80. Greendale GA, FitzGerald G, Huang M-H, Sternfeld B, Gold E, Seeman T, Sherman S, Sowers M. Dietary soy isoflavones and bone mineral density: results from the study of women's health across the nation. *Am J Epidemiol* 2002;155:746–54.
81. Rosano T, Nardo L, D'Agosta S, Savoca S, Maugeri G, Nardo F. Efficacy of treatment with phytoestrogens on vasomotor symptoms and on bone mineral density in postmenopausal women. *G Ital di Ostet e Ginecol* 2001;23:343–5.
82. Shedd-Wise KM, Alekel DL, Hofmann H, Hanson KB, Schiffl DJ, Hanson LN, Van Loan MD. The soy isoflavones for reducing bone loss study: 3-yr effects on pQCT bone mineral density and strength measures in postmenopausal women. *J Clin Densitom* 2011;14:47–57.
83. Rashid A, Khurshid R, Latif A, Ahmad N, Aftab L. Role of phytoestrogen in suppressing bone turnover in a group of postmenopausal women. *J Ayub Med Coll Abbottabad* 2010;22:201–4.
84. Wong WW, Lewis RD, Steinberg FM, Murray MJ, Cramer MA, Amato P, Young RL, Barnes S, Ellis KJ, Shypailo RJ, et al. Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-yr multicenter clinical trial. *Am J Clin Nutr* 2009;90:1433–9.
85. Powles TJ, Howell A, Evans DG, McCloskey EV, Ashley S, Greenhalgh R, Affen J, Flook LA, Tidy A. Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. *Menopause Int* 2008;14:6–12.
86. Wu J, Oka J, Tabata I, Higuchi M, Toda T, Fuku N, Ezaki J, Sugiyama F, Uchiyama S, Yamada K, et al. Effects of isoflavone and exercise on BMD and fat mass in postmenopausal Japanese women: a 1-year randomized placebo-controlled trial. *J Bone Miner Res* 2006;21:780–9.
87. Arjmandi BH, Lucas EA, Khalil DA, Devareddy L, Smith BJ, McDonald J, Arquitt AB, Payton ME, Mason C. One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. *Nutr J* 2005;4:8.
88. Atteritano M, Mazzaferro S, Frisina A, Cannata ML, Bitto A, D'Anna R, Squadrito F, Macri I, Frisina N, Buemi M. Genistein effects on quantitative ultrasound parameters and bone mineral density in osteopenic postmenopausal women. *Osteoporos Int* 2009;20:1947–54.
89. Öztürk Turhan N, Bolkan F, Iltemir Duvan C, Ardiçoğlu Y. The effect of isoflavones on bone mass and bone remodelling markers in postmenopausal women. *Turk J Med Sci* 2008;38:145–52.
90. Kok L, Kreijkamp-Kaspers S, Grobbee DE, van der Schouw YT. Design and baseline characteristics of a trial on health effects of soy protein with isoflavones in postmenopausal women. *Maturitas* 2004;47:21–9.
91. Alekel DL, Van Loan MD, Koehler KJ, Hanson LN, Stewart JW, Hanson KB, Kurzer MS, Peterson CT. The soy isoflavones for reducing bone loss (SIRBL) study: a 3-y randomized controlled trial in postmenopausal women. *Am J Clin Nutr* 2010;91:218–30.
92. Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect of soy protein isolate on bone metabolism. *Menopause* 2004;11:290–8.
93. Brink E, Coxam V, Robins S, Wahala K, Cassidy A, Branca F; PHYTOS Investigators. Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study. *Am J Clin Nutr* 2008;87:761–70.
94. Tit DM, Bungau SG, Cioara F, Suciuc RN. Comparative study on the effects of hormone replacement therapy and phytoestrogens in the prevention of the postmenopausal osteoporosis. *Osteoporos Int* 2015;26 (Suppl. 1);S245:P480.
95. Lappe J, Kunz I, Bendik I, Prudence K, Weber P, Recker R, Heaney RP. Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study. *Eur J Nutr* 2013;52:203–15.
96. Shedd-Wise KM, Hofmann H, Alekel DL, VanLoan M. Soy isoflavones for three years exert modest effects on pQCT bone measures in postmenopausal women. *FASEB J* 2010;24(Suppl):93–6.
97. Dotlic J, Terzic M, Mihailovic T, Maricic S. The effects of red clover derived isoflavones on serum lipids, bone turnover, and bone density in postmenopausal women. *J Gynecol Obstet* 2009;107:S651.
98. Lambert M, Jeppesen P. The effects of bioavailable red clover isoflavones for menopausal symptoms and associated diseases. *Planta Med* 2014;80:SL46.
99. Levis S, Strickman-Stein N, Doerge DR, Krischer J. Design and baseline characteristics of the soy phytoestrogens as replacement estrogen (SPARE) study—a clinical trial of the effects of soy isoflavones in menopausal women. *Contemp Clin Trials* 2010;31:293–302.
100. Chen Y-M, Ho SC, Lam SSH, Ho SSS, Woo JLF. Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: a double-blind, randomized, controlled trial. *Menopause* 2004;11:246–54.
101. Gallagher JC. Effect of early menopause on bone mineral density and fractures. *Menopause* 2007;14:567–71.
102. Bord S, Horner A, Beavan S, Compston J. Estrogen receptors  $\alpha$  and  $\beta$  are differentially expressed in developing human bone 1. *J Clin Endocrinol Metab* 2001;86:2309–14.
103. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A, Heubi JE. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. *J Nutr* 2001;131:1362S–75S.
104. Andres S, Hansen U, Niemann B, Palavinskas R, Lampen A. Determination of the isoflavone composition and estrogenic activity of commercial dietary supplements based on soy or red clover. *Food Funct* 2015;6:2017–25.
105. Prabhakaran MP, Hui LS, Perera CO. Evaluation of the composition and concentration of isoflavones in soy based supplements, health products and infant formulas. *Food Res Int* 2006;39:730–8.
106. Vitale DC, Piazza C, Melilli B, Drago F, Salomone S. Isoflavones: estrogenic activity, biological effect and bioavailability. *Eur J Drug Metab Pharmacokin* 2013;38:15–25.
107. Dören M. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. *Hum Reprod* 2003;18:1737–46.
108. Schott AM, Cormier C, Hans D, Favier F, Hausherr E, Dargent-Molina P, Delmas PD, Ribot C, Sebert JL, Breart G, et al. How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS prospective study. *Osteoporos Int* 1998;8:247–54.
109. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, et al. Predictive value of BMD for hip and other fractures. *J Bone Miner Res* 2005;20:1185–94.
110. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. *Endocr Rev* 2000;21:115–37.